Three clinical programs present diversified opportunities in and outside the existing anti-VEGF market and are being progressed toward Phase 3 value inflection points New Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy actively recruiting Phase 1b study of KSI-101 planned for…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.